Emcure Pharmaceuticals delivered a robust performance in FY26, crossing the US$1 billion revenue milestone with 16.6% year-on-year growth. The company achieved an adjusted PAT growth of over 40% and improved its EBITDA margin by 83 basis points to 19.4%. Driven by strong international momentum and a resilient domestic portfolio, the company successfully executed its first year of a five-year strategic roadmap while expanding its footprint through key global acquisitions and partnerships.
Financial Performance Highlights
Emcure Pharmaceuticals showcased strong financial health in FY26, reporting a total revenue of ₹9,204 crore, representing a 16.6% increase over the previous year. The company’s profitability saw significant gains, with Adjusted PAT reaching ₹1,008 crore, a robust 40.9% growth. These results underscore the effectiveness of the company’s ongoing efforts in productivity enhancement and the strategic scaling of its in-house product portfolio.
International and Domestic Market Momentum
The company’s international business remains a core growth driver, contributing 60% of total revenue in the final quarter. The international segment delivered 22.2% year-on-year growth for the full year, led by strong momentum in emerging markets, Europe, and Canada. Key factors included the successful integration of Manx, ramp-ups in the base business, and the strategic launch of Amphotericin B. Simultaneously, the domestic business remained resilient, growing 10% and benefiting from strong leadership in the Cardiac, CNS, and Oncology segments.
Strategic Expansion and R&D Progress
Emcure continues to advance its R&D pipeline, focusing on complex injectables, biosimilars, and antibody-drug conjugates (ADCs). Notable progress includes the CDSCO Subject Expert Committee endorsement for Biosimilar Bevacizumab and the filing of a DMF for Lenacapavir. Portfolio expansion was bolstered by new partnerships, including a collaboration with Novo Nordisk for the obesity-management drug Poviztra, the expansion of its Sanofi anti-diabetic partnership, and a distribution agreement with Roche for renal and transplant products.
Operational Efficiency and Future Outlook
Operational discipline resulted in an EBITDA of ₹1,789 crore for FY26. The company successfully navigated a seasonally weak quarter in Q4FY26 while maintaining a solid return on capital employed (ROCE) of 23.7%. With the consolidation of Zuventus and strategic acquisitions in Europe and Canada, Emcure is well-positioned to continue its momentum as it progresses through the second year of its five-year strategic roadmap.
Source: BSE
